The present invention provides to a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.

Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD47 blockade.

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.

Provided are conjugates between (a) an antibody or antigen-binding fragment thereof that binds to p97 (melanotransferrin; MTf) and (b) an agent of interest, and related compositions and methods, for example, to improve pharmacokinetics and/or delivery of the agent of interest across the blood-brain barrier (BBB) and into tissues of the central nervous system (CNS).

Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same. The antibodies provided include amino acid substitution embodiments affecting the antibody glycosylation state. The antibodies provided herein are, inter alia, useful for the treatment of cancer and effective for inhibition of CD73 activity.

The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.

The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.

The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.